

# **An optimised patient-derived explant platform for breast cancer reflects clinical responses to chemotherapy and antibody-directed therapy**

Constantinos Demetriou<sup>1</sup>, Naila Abid<sup>1</sup>, Michael Butterworth<sup>1</sup>, Larissa Lezina<sup>1</sup>, Pavandeep Sandhu<sup>1</sup>, Lynne Howells<sup>1</sup>, Ian R Powley<sup>1</sup>, James Howard Pringle<sup>1</sup>, Zahirah Sidat<sup>2</sup>, Omar Qassid<sup>1,3</sup>, Dave Purnell<sup>3</sup>, Monika Kaushik<sup>4</sup>, Kaitlin Duckworth<sup>4</sup>, Helen Hartshorn<sup>4</sup>, Anne Thomas<sup>1</sup>, Jacqui A Shaw<sup>1</sup>, Marion MacFarlane<sup>5,6\*</sup>, Catrin Pritchard<sup>1\*</sup>, Gareth J Miles<sup>1\*</sup>

Additional File 9: BC-PDE responses to FET + Trastuzumab


40 BC-PDEs were treated with FET + Trastuzumab or FET treatment alone. tumour apoptosis and combined tumour apoptosis and necrosis values in FET only treated BC-PDEs were subtracted from patient matched FET+Trastuzumab treated BC-PDEs to evaluate the additive effect of Trastuzumab on tumour cell killing above FET only treatment.

**A**, Percent change in tumour apoptosis of FET+ Trastuzumab treated BC-PDEs subtracting FET-induced tumour apoptosis related to HER2 status

**B**, Percent change in combined tumour apoptosis and necrosis of FET + Trastuzumab treated BC-PDEs subtracting FET-induced tumour apoptosis and necrosis related to HER2 status.

Additional File 9

A



B

